Clare Arnott's Publications

About Clare Arnott's Publications

Global Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

    Journal of the American Heart Association Date published:

  • Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

    Circulation Date published:

  • Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial

    Kidney International Reports Date published:

  • The Effect of Weight Loss Through Lifestyle Interventions in Patients With Heart Failure With Preserved Ejection Fraction-A Systematic Review and Meta-Analysis of Randomised Controlled Trials

    Heart, Lung and Circulation Date published:

  • A life-course approach to tackling noncommunicable diseases in women

    Nature Medicine Date published:

  • Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial

    International Journal of Cardiology Date published:

  • Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

    Journal of the American Society of Nephrology Date published:

  • Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes

    Kidney International Date published:

  • Protocol for a randomized controlled trial of medically tailored meals compared to usual care among individuals with type 2 diabetes in Australia

    Contemporary Clinical Trials Date published:

  • Developing a clinical pathway for breathlessness in primary care based on analysis of routine primary care data

    General practice and primary care Date published:

  • Development of patient resources for chronic breathlessness: Needs analysis

    General practice and primary care Date published:

  • The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Artificial Intelligence in Cardiology: An Australian Perspective

    Heart, Lung and Circulation Date published:

  • Risks and Burdens of Unplanned Heart Failure Readmissions: How to Cut a Gordian Knot?

    Heart, Lung and Circulation Date published:

  • Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

    American Journal of Kidney Diseases Date published: